Armata Pharmaceuticals, Inc. (ARMP) 已获得美国食品药品监督管理局（FDA）的认可，就其针对AP-SA02用于治疗复杂性金黄色葡萄球菌菌血症的初始儿科研究计划达成一致。这一进展标志着该候选疗法在应对儿童严重细菌感染方面迈出了重要一步。
Armata Pharmaceuticals, Inc. (ARMP) 已获得美国食品药品监督管理局（FDA）的认可，就其针对AP-SA02用于治疗复杂性金黄色葡萄球菌菌血症的初始儿科研究计划达成一致。这一进展标志着该候选疗法在应对儿童严重细菌感染方面迈出了重要一步。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.